19 Blue World In 2030, organisations begin to realise the benefits of human enhancement in the workplace. An online news report from 2030 details the first large-scale use of cognitive ‑ e nhancing drugs. F u t u r e v i e w World News 3 May 2030 09.30 ET Drumhum Inc leads the pack in the use of cognitive-enhancing drugs in the workplace as companies begin to realise their benefits. Drumhum Inc, the first large employer to offer cognitive ‑ e nhancing medication to its employees, says it has seen a 4% increase in productivity during the first three months of the financial year. Drumhum offered the methylpehnidate ‑ b ased drug Cognitalin, the first cognitive enhancer to be mass produced specifically for use in the workplace, to its employees on a voluntary basis at the beginning of the year. “The programme,” said Nancy Cole, the company’s Head of People Performance, “was closely monitored; it was also heavily oversubscribed, with more than 73% of Drumhum’s 3,000 workers based in the US volunteering to take part.” Cognitalin, a modified methylphenidate substitute developed by PharmaXcog, increases concentration and enhances memory function by increasing the synaptic concentration of the neurotransmitters dopamine and noradrenaline by blocking their reuptake and stimulating the prefrontal cortical network. It was licenced for non ‑ m edical use in 2027 following the publication of the Ethical Charter on Workplace Enhancement. Drumhum measured the performance of the Cognitalin group against a control group of employees of similar experience and demographics, who continued with Drumhum’s standard programme of gaming ‑ based cognitive training. “The group taking Cognitalin,” said Cole, “proved significantly more productive, completing a complex coding exercise around 10% more quickly than the control group – with 4% fewer errors.” Read more